ALPMF (Astellas Pharma) Debt-to-Revenue : 0.44 (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Astellas Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $2,144 Mil. Astellas Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3,807 Mil. Astellas Pharma's annualized Revenue for the quarter that ended in Dec. 2024 was $13,455 Mil. Astellas Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.44.

Astellas Pharma Debt-to-Revenue Historical Data

The historical data trend for Astellas Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Debt-to-Revenue Chart

Astellas Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Revenue

Get a 7-Day Free Trial

0.08

0.57

Astellas Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															0.52	0.56	0.53	0.50	0.44

Competitive Comparison of Astellas Pharma's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Astellas Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Astellas Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Astellas Pharma's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3152.332	+	2988.534)	/	10704.091
	=	0.57

Astellas Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2144.489	+	3806.61)	/	13455.392
	=	0.44

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Astellas Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.